TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses
The Pharma Data
DECEMBER 27, 2020
million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. TLC599 is a non-opioid, proprietary BioSeizer ® sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.
Let's personalize your content